MacroGenics | MGNX - Current Assets


MacroGenics reported $295.08M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Amgen USD 34.36B 598M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Daiichi Sankyo JPY 2.38T 150.33B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Genmab DKK 2.8B 228M Jun/2026
Geron USD 468.74M 17.6M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Xencor USD 498.66M 24.55M Sep/2026